Ivermectin Could Be Safely Used in Young Children, Expanding Fight Against Tropical Diseases
A new clinical trial suggests that millions of young children currently excluded from treatment with the drug ivermectin could be safely included in mass drug administration (MDA) campaigns targeting neglected tropical diseases. The findings, presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), offer hope for a more extensive approach to combating illnesses like intestinal worms, scabies, and river blindness.
A double-blind study conducted in Gambia, Kenya, and Brazil with 240 participants revealed that ivermectin can be administered to young children weighing as little as 5 kilograms (approximately 11 pounds) without apparent adverse effects.This is a significant advancement,as current manufacturer labeling restricts use to children weighing 15 kilograms or more.
“Our study found that ivermectin can be given to young children who weigh as little 5 kilograms or about 11 pounds-and that’s significant as these children are particularly vulnerable to the many diseases currently treatable by ivermectin,” explained a lead author of the study, kevin Kobylinski, PhD, a University of Oxford honorary visiting research fellow with the Mahidol Oxford Tropical Medicine Research Unit in bangkok. The research team noted that a prior analysis of numerous ivermectin studies indicated instances where children as young as 5 kilograms had received the drug without reported serious complications, prompting further investigation.
The Impact of Including Young Children in MDA Campaigns
Mass drug administration campaigns, where entire villages receive medication, are a cornerstone of global efforts to control and eliminate several debilitating diseases. Excluding children under 15 kilograms significantly limits the reach and effectiveness of these programs. According to the study, including younger children could yield substantial benefits:
- Young children are disproportionately affected by stunting and cognitive impairments resulting from infections with ivermectin-susceptible intestinal worms.
- Evidence suggests ivermectin can suppress malaria transmission, but achieving the necessary 70% population coverage for effectiveness is challenging when excluding young children.
- Onchocerciasis, or river blindness, is a primary target of ivermectin MDA campaigns. While delaying treatment until older can prevent vision loss, early infections may trigger immune responses leading to nodding syndrome, a severe form of epilepsy.
- Young children are particularly susceptible to scabies, a parasitic infestation that can cause intense itching, skin sores, and secondary bacterial infections.
The potential for broader impact is substantial. “Ivermectin has provided a foundation of some of the most triumphant interventions in global health, and evidence that it might very well be safely given to young children could help this work achieve an even greater impact,” stated David Fidock, PhD, the CS Hamish Young Professor of Microbiology and Immunology and Professor of Medical Sciences at Columbia University Irving Medical Center, and current ASTMH President.
The outcomes of the “Iver
The study, funded by the Bill & Melinda Gates Foundation, directly addressed this limitation. Researchers meticulously monitored the 240 children-divided into groups receiving different ivermectin doses or a placebo-for any adverse reactions. The results consistently showed no significant safety concerns, even at the lowest weight category of 5-10 kilograms. This finding is crucial because it challenges existing restrictions and opens the door for expanded MDA programs.
Why was this study conducted? Existing guidelines limited ivermectin use to children weighing 15kg or more, excluding a vulnerable population. Researchers aimed to determine if lower doses were safe for younger, lighter children. Who conducted the study? The research was led by Kevin Kobylinski, PhD, of
